Back

Longeveron shares plunge 60% after heart therapy fails late-stage trial

Verifying
  • Longeveron disclosed that laromestrocel failed to beat control treatment in the Elpis II trial.
  • Shares fell 60% to $2.70 in extended trading Wednesday.
  • The study enrolled 40 infants with hypoplastic left heart syndrome.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.